Fig. 4From: Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II studyCumulative overall survival curve of the study population (n = 30). The median overall survival of the whole patient collective was 40.6 month (95% CI 18.8–62.3) with a 3-year OS of 55.7 ± 9.2%Back to article page